

Supplementary Materials

Supplementary Table 1. Clinical diagnosis of other cases

Supplementary Table 2. Diagnostic criteria used in this study

Supplementary Table 3. Cutoff values of A β 42/A β 40 ratio

Supplementary Table 4. Demographic characteristics and biomarkers in clinically diagnosed group

Supplementary Table 5. Demographic characteristics and biomarkers of ACS subgroups

Supplementary Figure 1. The cutoff values of A β 42/A β 42 ratio

Supplementary Figure 2. Levels of CSF biomarkers in patients with ACS and non-ACS

Supplementary Figure 3. Levels of CSF biomarkers in each clinical diagnosis

Supplementary Figure 4. Distribution of patients according to CSF levels of A β 42 and A β 42/A β 40 ratio

Supplementary Figure 5. Distribution of patients according to CSF levels of tTau and NfL

Supplementary Figure 6. Distribution of patients according to CSF levels of pTau and A β 42 or A β 42/A β 40 ratio

Supplementary Table 1. Clinical diagnosis of other cases

Clinical diagnosis	Number of patients
Autoimmune encephalitis	5
Subjective cognitive decline	4
Psychiatric disorders	3
Epilepsy	3
Creutzfeldt-Jakob disease	3
Amyotrophic lateral sclerosis	3
Argyrophilic grain disease	3
Diffuse neurofibrillary tangles with calcification	3
Neuronal intranuclear inclusion disease	3
Alcoholic dementia	3
Cerebral infarction	2
Globular glial tauopathy	1
Hereditary diffuse leukoencephalopathy with axonal spheroids	1
Parkinsonian syndrome	1
Spinocerebellar ataxia	1
Cerebellar ataxia	1
Gait disturbance	1
Myotonic dystrophy	1
Multiple sclerosis	1
Hashimoto's encephalitis	1
Paraneoplastic neurological syndrome	1
Bromvaleryl urea poisoning	1
Vitamin B12 deficiency	1
Drug-induced parkinsonism	1
Posterior reversible encephalopathy syndrome	1
Cerebral hemorrhage	1
Sequelae of cerebral hemorrhage	1
Non-communicating hydrocephalus	1
Cerebellar atrophy	1
Hippocampal atrophy	1
Total	54

Supplementary Table 2. Diagnostic criteria used in this study

Disease	Clinical diagnostic criteria
Alzheimer's disease dementia	McKhann GM, et al. <i>Alzheimers Dement</i> 2011
Posterior cortical atrophy	Tang-Wai DF, et al. <i>Neurology</i> 2004 Crutch SJ, et al. <i>Alzheimers Dement</i> 2017
Logopenic variant primary progressive aphasia	Gorno-Tempini ML, et al. <i>Neurology</i> 2011
Mild cognitive impairment due to Alzheimer's disease	Albert MS, et al. <i>Alzheimers Dement</i> 2011
Cerebral amyloid angiopathy	Knudsen KA, et al. <i>Neurology</i> 2001
Vascular cognitive impairment	Gorelick PB, et al. <i>Stroke</i> 2011 Skrobot OA, et al. <i>Alzheimers Dement</i> 2017
Dementia with Lewy bodies	McKeith IG, et al. <i>Neurology</i> 2005 McKeith IG, et al. <i>Neurology</i> 2017
Mild cognitive impairment with Lewy bodies	McKeith IG, et al. <i>Neurology</i> 2020
Parkinson's disease with dementia	Emre M, et al. <i>Mov Disord</i> 2007
Mild cognitive impairment with Parkinson's disease	Litvan I, et al. <i>Mov Disord</i> 2012
Parkinson's disease	Litvan I, et al. <i>Mov Disord</i> 2003 Postuma RB, et al. <i>Mov Disord</i> 2015
Multiple system atrophy	Gliman S, et al. <i>Neurology</i> 2008
Corticobasal syndrome	Armstrong MJ, et al. <i>Neurology</i> 2013
Progressive nuclear palsy	Litvan I, et al. <i>Neurology</i> 1996 Hoglinger GU, et al. <i>Mov Disord</i> 2017
Behavioral variant frontotemporal dementia	Rascovsky K, et al. <i>Brain</i> 2011
Semantic variant primary progressive aphasia	Gorno-Tempini ML, et al. <i>Neurology</i> 2011
Non-fluent variant primary progressive aphasia	Gorno-Tempini ML, et al. <i>Neurology</i> 2011
Idiopathic normal pressure hydrocephalus	Mori E, et al. <i>Neurol Med Chir (Tokyo)</i> 2012 Nakajima M, et al. <i>Neurol Med Chir (Tokyo)</i> 2021

Supplementary Table 3. Cutoff values of A β 42/A β 40 ratio

Aβ PET– (n = 42) vs Aβ PET+ (n = 46)	
Cutoff value	<0.068
AUC (95% CI)	0.94 (0.87-1.00)
Sensitivity, % (95% CI)	100 (92.3-100)
Specificity, % (95% CI)	92.9 (81.0-97.5)
CU, Aβ PET– (n = 26) vs ADD, Aβ PET+ (n = 20)	
Cutoff value	<0.065
AUC (95% CI)	0.97 (0.90-1.00)
Sensitivity, % (95% CI)	100 (83.9-100)
Specificity, % (95% CI)	96.2 (81.1-99.8)
CU (n = 46) vs ADD (n = 49)	
Cutoff value	<0.068
AUC (95% CI)	0.93 (0.87-0.99)
Sensitivity, % (95% CI)	98.0 (89.3-99.9)
Specificity, % (95% CI)	87.0 (74.3-93.9)
Gaussian Mixture Model (n = 177)	
Cutoff value	<0.072

A β : β -amyloid; ADD: Alzheimer's disease dementia; AUC: Area Under the Curve; CU: cognitively unimpaired

Supplementary Table 4. Demographic characteristics and biomarkers in clinically diagnosed group

	Probable AD (n = 145)	Possible AD (n = 26)	MCI due to AD (n = 59)	CAA (n = 28)	VCI (n = 23)	LBD (n = 51)
Age at LP, y	73 (62, 81)	78 (67, 80)	77 (73, 81)	72 (63, 79)	76 (73, 81)	77 (71, 82)
Female/Male, n (% female)	89/56 (61.4)	14/12 (53.8)	35/24 (59.3)	18/10 (64.3)	12/11 (52.2)	21/30 (41.2)
MMSE score	20 (14, 23)	18 (16, 21)	23 (20, 26)	15 (5, 23)	24 (20, 26)	25 (20, 27)
A β 42, pg/mL	254.5 (204.2, 331.7)	259.7 (164.1, 368.3)	295.2 (240.4, 373.8)	229.6 (128.7, 295.2)	307.7 (244.7, 436.1)	308.9 (232.1, 448.8)
A β 42/A β 40 ratio	0.047 (0.039, 0.066)	0.058 (0.041, 0.082)	0.051 (0.043, 0.079)	0.060 (0.040, 0.079)	0.072 (0.055, 0.088)	0.076 (0.046, 0.091)
pTau, pg/mL	44.3 (29.5, 57.8)	28.9 (22.1, 35.5)	48.1 (36.4, 62.8)	25.1 (19.5, 32.9)	32.1 (23.8, 38.8)	35.6 (24.7, 49.2)
tTau, pg/mL	86.2 (61.0, 111.1)	66.5 (51.5, 81.7)	89.0 (66.1, 108.3)	60.2 (50.5, 87.2)	73.7 (57.0, 85.9)	65.0 (56.9, 91.3)
NfL, pg/mL	4213.5 (3138.4, 6480.9)	5397.1 (3502.5, 21626.2)	4009.5 (2819.9, 5594.8)	11568.8 (6396.2, 42087.5)	8232.4 (4120.9, 15110.8)	3903.4 (3086.6, 5886.8)
A β 42-alone ⁻ /A β -ratio ⁻ , n (%)	21 (14.5)	5 (19.2)	13 (22.0)	3 (10.7)	8 (34.8)	18 (35.3)
A β 42-alone ⁻ /A β -ratio ⁺ , n (%)	6 (4.1)	2 (7.7)	4 (6.8)	1 (3.6)	0 (0)	2 (3.9)
A β 42-alone ⁺ /A β -ratio ⁻ , n (%)	9 (6.2)	4 (15.4)	4 (6.8)	8 (28.6)	3 (13.0)	9 (17.6)
A β 42-alone ⁺ /A β -ratio ⁺ , n (%)	109 (75.2)	15 (57.7)	38 (64.4)	16 (57.1)	12 (52.2)	22 (43.1)
N _{tau} ⁻ /N _{NfL} ⁻ , n (%)	23 (15.9)	3 (11.5)	9 (15.3)	1 (3.6)	2 (8.7)	9 (17.6)
N _{tau} ⁻ /N _{NfL} ⁺ , n (%)	81 (55.9)	20 (76.9)	31 (52.5)	21 (75.0)	18 (78.3)	32 (62.7)
N _{tau} ⁺ /N _{NfL} ⁻ , n (%)	4 (2.8)	0 (0)	1 (1.7)	0 (0)	0 (0)	0 (0)
N _{tau} ⁺ /N _{NfL} ⁺ , n (%)	37 (25.5)	3 (11.5)	18 (30.5)	6 (21.4)	3 (13.0)	10 (19.6)
A β 42-alone ⁻ /T ⁻ , n (%)	13 (9.0)	5 (19.2)	7 (11.9)	3 (10.7)	3 (13.0)	7 (13.7)
A β 42-alone ⁻ /T ⁺ , n (%)	14 (9.7)	2 (7.7)	10 (16.9)	1 (3.6)	5 (21.7)	13 (25.5)
A β 42-alone ⁺ /T ⁻ , n (%)	25 (17.2)	11 (42.3)	4 (6.8)	18 (64.3)	8 (34.8)	14 (27.5)
A β 42-alone ⁺ /T ⁺ , n (%)	93 (64.1)	8 (30.8)	38 (64.4)	6 (21.4)	7 (30.4)	17 (33.3)
A β -ratio ⁻ /T ⁻ , n (%)	21 (14.5)	8 (30.8)	10 (16.9)	11 (39.3)	6 (26.1)	15 (29.4)
A β -ratio ⁻ /T ⁺ , n (%)	9 (6.2)	1 (3.8)	7 (11.9)	0 (0)	5 (21.7)	12 (23.5)
A β -ratio ⁺ /T ⁻ , n (%)	17 (11.7)	8 (30.8)	1 (1.7)	10 (35.7)	5 (21.7)	6 (11.8)
A β -ratio ⁺ /T ⁺ , n (%)	98 (67.6)	9 (34.6)	41 (69.5)	7 (25.0)	7 (30.4)	18 (35.3)

(continued)

Supplementary Table 4 (continued)

	MSA (n = 10)	CBS (n = 35)	PSP (n = 29)	FTLD (n = 46)	iNPH (n = 91)	Unclassified (n = 43)
Age at LP, y	69 (61, 70)	69 (64, 75)	78 (72, 82)	68 (61, 76)	78 (75, 81)	75 (64, 81)
Female/Male, n (% female)	5/5 (50.0)	23/12 (65.7)	17/12 (58.6)	22/24 (47.8)	46/45 (50.5)	19/24 (44.2)
MMSE score	28 (26, 30)	24 (18, 25)	26 (18, 29)	23 (17, 26)	22 (18, 25)	25 (20, 26)
A β 42, pg/mL	225.1 (200.1, 250.4)	334.9 (186.9, 445.5)	251.2 (196.5, 373.6)	328.5 (244.4, 424.0)	261.3 (191.1, 344.6)	313.9 (203.1, 393.9)
A β 42/A β 40 ratio	0.076 (0.064, 0.082)	0.080 (0.055, 0.088)	0.072 (0.063, 0.092)	0.082 (0.053, 0.090)	0.076 (0.059, 0.088)	0.065 (0.051, 0.087)
pTau, pg/mL	18.1 (17.0, 21.3)	30.1 (23.6, 35.6)	21.1 (15.8, 30.5)	28.9 (19.2, 38.8)	22.9 (16.7, 30.6)	26.7, (22.0, 35.1)
tTau, pg/mL	59.1 (54.1, 61.4)	59.8 (45.9, 83.6)	50.5 (36.8, 56.1)	72.0 (51.4, 89.0)	44.8 (33.5, 58.0)	47.8 (39.8, 67.8)
NfL, pg/mL	17378.7 (10174.2, 19234.1)	8043.5 (5715.9, 10445.6)	7053.5 (4005.8, 9770.2)	6891.7 (4682.7, 9979.4)	4294.6 (3163.6, 9554.2)	3596.4 (2337.4, 4825.7)
A β 42-alone ⁻ /A β -ratio ⁻ , n (%)	1 (10.0)	14 (40.0)	8 (27.6)	19 (41.3)	20 (22.0)	14 (32.6)
A β 42-alone ⁻ /A β -ratio ⁺ , n (%)	0 (0)	0 (0)	1 (3.4)	0 (0)	2 (2.2)	2 (4.7)
A β 42-alone ⁺ /A β -ratio ⁻ , n (%)	5 (50.0)	8 (22.9)	6 (20.7)	9 (19.6)	31 (34.1)	7 (16.3)
A β 42-alone ⁺ /A β -ratio ⁺ , n (%)	4 (40.0)	13 (37.1)	14 (48.3)	18 (39.1)	38 (41.8)	20 (46.5)
N _{tau} ⁻ /N _{NfL} ⁻ , n (%)	0 (0)	2 (5.7)	2 (6.9)	1 (2.2)	15 (16.5)	11 (25.6)
N _{tau} ⁻ /N _{NfL} ⁺ , n (%)	10 (100)	27 (77.1)	26 (89.7)	35 (76.1)	72 (79.1)	26 (60.5)
N _{tau} ⁺ /N _{NfL} ⁻ , n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4.7)
N _{tau} ⁺ /N _{NfL} ⁺ , n (%)	0 (0)	6 (17.1)	1 (3.4)	10 (21.7)	4 (4.4)	4 (9.3)
A β 42-alone ⁻ /T ⁻ , n (%)	0 (0)	10 (28.6)	5 (17.2)	12 (26.1)	17 (18.7)	13 (30.2)
A β 42-alone ⁻ /T ⁺ , n (%)	1 (10.0)	4 (11.4)	4 (13.8)	7 (15.2)	5 (5.5)	3 (7.0)
A β 42-alone ⁺ /T ⁻ , n (%)	8 (80.0)	10 (28.6)	17 (58.6)	14 (30.4)	51 (56.0)	16 (37.2)
A β 42-alone ⁺ /T ⁺ , n (%)	1 (10.0)	11 (31.4)	3 (10.3)	13 (28.3)	18 (19.8)	11 (25.6)
A β -ratio ⁻ /T ⁻ , n (%)	5 (50.0)	16 (45.7)	10 (34.5)	21 (45.7)	45 (49.5)	19 (44.2)
A β -ratio ⁻ /T ⁺ , n (%)	1 (10.0)	6 (17.1)	4 (13.8)	7 (15.2)	6 (6.6)	2 (4.7)
A β -ratio ⁺ /T ⁻ , n (%)	3 (30.0)	4 (11.4)	12 (41.4)	5 (10.9)	23 (25.3)	10 (23.3)
A β -ratio ⁺ /T ⁺ , n (%)	1 (10.0)	9 (25.7)	3 (10.3)	13 (28.3)	17 (18.7)	12 (27.9)

Data shown are median (interquartile range) unless otherwise indicated. A β : β -amyloid; AD: Alzheimer's disease; CAA: cerebral amyloid angiopathy; CBS: corticobasal syndrome; FTLD: frontotemporal lobar degeneration; iNPH: idiopathic normal pressure hydrocephalus; LBD: Lewy body disease; LP: lumbar puncture; MCI: mild cognitive impairment; MMSE: Mini-Mental State Examination; MSA: multiple system atrophy; NfL: neurofilament light chain; PSP: progressive


supranuclear palsy; pTau: phosphorylated tau (Thr181); tTau: total tau; VCI: vascular cognitive impairment

Supplementary Table 5. Demographic characteristics and biomarkers of ACS subgroups

	ACS, <65 years (n = 59)	ACS, ≥65 years (n = 171)	<i>p</i> -value
Age at LP, y	57 (54, 61)	78 (73, 83)	<0.0001
Female/Male, n (% female)	30/29 (50.8)	108/63 (63.2)	0.0961
MMSE score	20 (17, 24)	21 (17, 24)	0.9631
Aβ ₄₂ , pg/mL	247.8 (171.8, 337.5)	267.8 (216.4, 352.4)	0.3270
Aβ ₄₂ /Aβ ₄₀ ratio	0.046 (0.039, 0.075)	0.051 (0.040, 0.071)	0.8498
pTau, pg/mL	45.3 (32.9, 58.9)	43.2 (28.4, 57.5)	0.3181
tTau, pg/mL	87.6 (61.7, 108.8)	83.7 (60.3, 106.8)	0.6640
NfL, pg/mL	3726.4 (2787.6, 4858.5)	4476.6 (3169.4, 6823.5)	0.3286
A _{Aβ42-alone} ⁻ /A _{Aβ-ratio} ⁻ , n (%)	12 (20.3)	27 (15.8)	0.1884
A _{Aβ42-alone} ⁻ /A _{Aβ-ratio} ⁺ , n (%)	0 (0)	12 (7.0)	
A _{Aβ42-alone} ⁺ /A _{Aβ-ratio} ⁻ , n (%)	4 (6.8)	13 (7.6)	
A _{Aβ42-alone} ⁺ /A _{Aβ-ratio} ⁺ , n (%)	43 (72.9)	119 (69.6)	
N _{tau} ⁻ /N _{NfL} ⁻ , n (%)	13 (22.0)	22 (12.9)	0.3764
N _{tau} ⁻ /N _{NfL} ⁺ , n (%)	30 (50.8)	102 (59.6)	
N _{tau} ⁺ /N _{NfL} ⁻ , n (%)	1 (1.7)	4 (2.3)	
N _{tau} ⁺ /N _{NfL} ⁺ , n (%)	15 (25.4)	43 (25.1)	
A _{Aβ42-alone} ⁻ /T ⁻ , n (%)	5 (8.5)	20 (11.7)	0.2727
A _{Aβ42-alone} ⁻ /T ⁺ , n (%)	7 (11.9)	19 (11.1)	
A _{Aβ42-alone} ⁺ /T ⁻ , n (%)	6 (10.2)	34 (19.9)	
A _{Aβ42-alone} ⁺ /T ⁺ , n (%)	41 (69.5)	98 (57.3)	
A _{Aβ-ratio} ⁻ /T ⁻ , n (%)	8 (13.6)	31 (18.1)	0.0579
A _{Aβ-ratio} ⁻ /T ⁺ , n (%)	8 (13.6)	9 (5.3)	
A _{Aβ-ratio} ⁺ /T ⁻ , n (%)	3 (5.1)	23 (13.5)	
A _{Aβ-ratio} ⁺ /T ⁺ , n (%)	40 (67.8)	108 (63.2)	


Data shown are median (interquartile range) unless otherwise indicated. Aβ: β-amyloid; LP: lumbar puncture; MMSE: Mini-Mental State Examination; NfL: neurofilament light chain; pTau: phosphorylated tau (Thr181); tTau: total tau

Supplementary Figure 1. The cutoff values of A β 42/A β 42 ratio




The cutoff values were determined between PET A β negative and positive participants (A), between cognitively unimpaired (CU) participants with PET A β negative and Alzheimer's disease dementia (ADD) patients with PET A β positive (B), and between CU subjects and ADD patients (C). The dotted lines in upper panels in each column indicate the cutoff values calculated according to the Youden's index. The lower panels in each column show the ROC curves to determine the cutoff values. In Gaussian mixture model (D), the cutoff values are estimated as the crossing point (vertical lines) of the prevalence-weighted densities.

Supplementary Figure 2. Levels of CSF biomarkers in patients with ACS and non-ACS




Each CSF biomarker level is shown (Aβ42, **A**; Aβ42/Aβ40 ratio, **B**; pTau, **C**; tTau, **D**; NfL, **E**). Two outliers of tTau within non-ACS are omitted from plots but retained in the statistical analyses. Group differences of CSF biomarker levels between ACS and non-ACS groups were assessed with logistic regression models that included age and sex as covariates. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Supplementary Figure 3. Levels of CSF biomarkers in each clinical diagnosis




CSF biomarkers in each clinical diagnosis are shown (Aβ42, **A**; Aβ42/Aβ40 ratio, **B**; pTau, **C**; tTau, **D**; NfL, **E**). One outlier of tTau with CAA is omitted from plots. AD, Alzheimer's disease; CAA, cerebral amyloid angiopathy; CBS, corticobasal syndrome; FTLD, frontotemporal lobar degeneration; iNPH, idiopathic normal pressure hydrocephalus; LBD, Lewy body disease; MCI, mild cognitive impairment; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; VCI, vascular cognitive impairment.

Supplementary Figure 4. Distribution of patients according to CSF A β 42 levels and A β 42/A β 40 ratio




Distribution of participants according to CSF levels of A β 42 and A β 42/A β 40 ratio in ACS group (A: filled circle, probable AD dementia; open square, possible AD dementia; open triangle, MCI due to AD), CAA (B), VCI (C: filled circle, major VCI [i.e., vascular dementia]; open triangle, mild VCI), LBD (D: filled circle, DLB or PD dementia; open triangle, prodromal DLB/non-demented PD), MSA (E), CBS (F), PSP (G), FTLN (H: filled circle, behavioural variant frontotemporal dementia; open triangle, semantic variant PPA; open square, non-fluent variant PPA; open diamond, other FTLN), iNPH (I), and unclassified dementia or MCI (J: filled circle, unclassified dementia; open triangle, unclassified MCI). Dashed lines indicate cutoffs. Spearman's rank correlation coefficient (r) and p -value are shown. One ACS case with $A_{\text{A}\beta 42\text{-alone}}^{-}/A_{\text{A}\beta\text{-ratio}}^{-}$ (A β 42 877.9 pg/mL, A β 42/A β 40 ratio 0.115) is omitted from plots but retained in statistical analyses.

Supplementary Figure 5. Distribution of patients according to CSF levels of tTau and NfL




Distribution of participants according to CSF levels of tTau and NfL in ACS group (A: filled circle, probable AD dementia; open square, possible AD dementia; open triangle, MCI due to AD), CAA (B), VCI (C: filled circle, major VCI [i.e., vascular dementia]; open triangle, mild VCI), LBD (D: filled circle, DLB or PD dementia; open triangle, prodromal DLB/non-demented PD), MSA (E), CBS (F), PSP (G), FTLD (H: filled circle, behavioural variant frontotemporal dementia; open triangle, semantic variant PPA; open square, non-fluent variant PPA; open diamond, other FTLD), iNPH (I), and unclassified dementia or MCI (J: filled circle, unclassified dementia; open triangle, unclassified MCI). Dashed lines indicate cutoffs. Spearman's rank correlation coefficient (r) and p -value are shown. One CAA case with $N_{\text{tau}}+N_{\text{NfL}}+$ (tTau 1198.7 pg/mL, NfL 228633.9 pg/mL), one VCI case with $N_{\text{tau}}+N_{\text{NfL}}+$ (tTau 305.4 pg/mL, NfL 160916.4 pg/mL), two LBD cases with $N_{\text{tau}}+N_{\text{NfL}}+$ (tTau 307.2 pg/mL, NfL 9647.2 pg/mL; tTau 483.6 pg/mL, NfL 232271.6 pg/mL), one iNPH case with $N_{\text{tau}}+N_{\text{NfL}}+$ (tTau 316.5 pg/mL, NfL 56705.4 pg/mL), and one unclassified case with $N_{\text{tau}}+N_{\text{NfL}}+$ (tTau 405.3 pg/mL, NfL 104784.2 pg/mL) are omitted from plots but retained in statistical analyses.

Supplementary Figure 6. Distribution of patients according to CSF levels of pTau and Aβ42 or Aβ42/Aβ40 ratio



(continued)

Supplementary Figure 6. Distribution of patients according to CSF levels of pTau and A β 42 or A β 42/A β 40 ratio



Distribution of participants according to CSF levels of pTau181 and A β 42 or A β 42/A β 40 ratio in ACS group (A, B: filled circle, probable AD dementia; open square, possible AD dementia; open triangle, MCI due to AD), CAA (C, D), VCI (E, F: filled circle, major VCI [i.e., vascular dementia]; open triangle, mild VCI), LBD (G, H: filled circle, DLB or PD dementia; open triangle, prodromal DLB/non-demented PD), MSA (I, J), CBS (K, L), PSP (M, N), FTLN (O, P: filled circle, behavioural variant frontotemporal dementia; open triangle, semantic variant PPA; open square, non-fluent variant PPA; open diamond, other FTLN), iNPH (Q, R), and unclassified dementia or MCI (S, T: filled circle, unclassified dementia; open triangle, unclassified MCI). Dashed lines indicate cutoffs. Two ACS cases with A β 42-alone^{+/T-}, one ACS case with A β -ratio^{-/T-}, one ACS case with A β -ratio^{+/T-}, two CAA cases with A β 42-alone^{+/T-}, one CAA case with A β -ratio^{-/T-}, one CAA case with A β -ratio^{+/T-}, one VCI case with A β 42-alone^{-/T-}, one VCI case with A β -ratio^{-/T-}, three CBS cases with A β 42-alone^{+/T-}, two CBS cases with A β -ratio^{-/T-}, one CBS case with A β -ratio^{+/T-}, three PSP cases with A β 42-alone^{+/T-}, one PSP case with A β -ratio^{-/T-}, two PSP cases with A β -ratio^{+/T-}, one FTLN case with A β 42-alone^{+/T-}, one FTLN case with A β -ratio^{-/T-}, six iNPH cases with A β 42-alone^{+/T-}, four iNPH cases with A β -ratio^{-/T-}, two iNPH cases with A β -ratio^{+/T-}, one unclassified case with A β 42-alone^{+/T-}, and one unclassified case with A β -ratio^{-/T-} have Lower limit of quantification of pTau.